1098 results about "Pyrimidine" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The invention relates to a pyrrolo [2, 3-d] pyrimidine-4-amine derivative and application thereof in medicine, in particular to a compound shown in a formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, pharmaceutically acceptable salt or eutectic of the compound, and application of the compound in preparation of medicines for treating sGC-related diseases.

This disclosure provides redox cyclable molecules for energy storage. These molecules belong to either the 4H-pyran-4-ylidene family or include a six-membered aromatic ring with one nitrogen atom at position 1 (pyridinium family) or two nitrogen atoms at positions 1 and 4 (pyrazinium family) or at positions 1 and 3 (pyrimidinium family). Molecules in these families are used as analytes in redox flow batteries.

The invention discloses an electron transport material, an electron transport layer and an organic electroluminescent device, and belongs to the technical field of organic electroluminescent materials. The electron transport material is a nitrogen-containing heterocyclic compound, and simultaneously contains a pyridine ring and a pyrimidine ring connected with the pyridine ring. By introducing a power supply group with a steric effect, the nucleophilicity of similar nitrogen atoms on a pyrimidine ring connected with a pyridine ring can be shielded, so that the coordination activation n-doping effect of a target chelated nitrogen atom and an n-type doping agent is enhanced, and the coordination stability in the coordination activation n-doping effect is promoted; by introducing a power-supplying group to modify the nitrogen-containing heterocyclic unit, the electron nucleophilicity of the nitrogen-containing heterocyclic unit is enhanced, so that the electron transport material can form a more stable complex with the n-type dopant, and the conductivity of the electron transport layer of the light-emitting device is improved; therefore, the driving voltage of the organic light-emitting device can be reduced, the efficiency of the device is improved, and the service life is prolonged.

The invention relates to a pyrimidine derivative as well as a pharmaceutical composition and application thereof, and particularly provides a compound as shown in the following formula H, and a raceme, a stereoisomer, a tautomer, an isotope label, a solvate, a polymorphic substance, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound.

The application discloses an indole-linked pyrimidine compound, an intermediate thereof, a preparation method and application thereof. The application provides an indole-linked pyrimidine compound shown as formula I or a pharmaceutically acceptable salt thereof, which has a good inhibiting effect on EGFR Del19 / T790M / C797S mutation, and is expected to treat and / or prevent various diseases mediated by EGFR.

The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.

Methods for treating Sickle Cell Disease (SCD) comprising administering a BTKi, such as at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof, are disclosed.

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

This invention belongs to the field of pesticides, specifically relating to a binary herbicidal composition comprising a substituted pyrimidine formyl compound and its application. The binary herbicidal composition includes an effective amount of active ingredient A and active ingredient B, wherein active ingredient A is active ingredient B or is Cyclopyranil. This composition effectively controls various weeds, including grasses and broadleaf weeds, and features a broadened weed control spectrum, reduced application rate, synergistic effect, and the ability to combat resistant weeds.

The compound cis)-N—((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4 methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide can be prepared as a free base in various crystalline solid forms, and in various salt forms each having one or more solid forms.

The present invention discloses a series of fused polycyclic substituted 5-carboxylic acid thienopyrimidinedione compounds and their uses, specifically, those of formula (II): The compound represented by TIFF2024507408000065.tif5475 and pharma- ceutically acceptable salts thereof are disclosed.

The application discloses an alkali ion type covalent organic framework material and a preparation method and application thereof, wherein 2,4,6-tris(4-formylphenyl)-1,3,5-triazine, 1,4-diisocyanobenzene and 2-aminopyridine are used as building units, a covalent organic framework containing pyrimidine is obtained through a condensation reaction, and then a quaternary ammonium reaction and an ion exchange reaction are sequentially performed to obtain the alkali ion type covalent organic framework.The alkali ion type covalent organic framework material prepared by the application has rich alkali sites, developed pore structures and good chemical stability, exhibits good catalytic performance as a catalyst for one-pot preparation of dimethyl carbonate from CO2, an epoxide compound and methanol, and also shows good cycle stability.

The present application provides compounds of Formula (I):or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

The present invention relates to salts of aminopyrimidine compounds and uses thereof. In particular, the present invention relates to salts of (S)-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5-(3-hydroxyprop-1-yn-1-yl)-3-phenylquinazolin-4(3H)-one and pharmaceutical compositions comprising said salts, further to their use in the manufacture of a medicament for the treatment and prevention of diseases associated with PI3K kinase abnormalities.

The invention discloses a 2-amino-4-(5-cyano-1-isopropyl-1H-indole-3-yl) pyrimidine compound and application thereof, the compound has the following structural general formula: in the formula, substituent R is substituted phenyl, the number of substituent groups on the benzene ring of the substituted phenyl is 1-2, and the substituent groups on the benzene ring of the substituted phenyl are 1-2. Substituent groups are respectively and independently selected from nitro, cyano, halogen, carbamoyl, furyl or pyridyl. The 2-amino-4-(5-cyano-1-isopropyl-1H-indole-3-yl) pyrimidine compound designed and synthesized by the invention is a novel efficient NF-kappa B induced kinase (NIK) inhibitor, and is suitable for drug development taking NF-kappa B induced kinase (NIK) as a target spot, and the obtained drug can be used for treating malignant tumors such as leukemia, multiple myeloma and the like.

The present application relates to a kind of five-ring thiazole indole ketone piperazine amide derivatives and purposes thereof.The derivatives take ethyl cyanoacetate as starting material, generate hydroxylamine compound (A) under the action of sodium nitrite and phosphoric acid;Obtain 2-amino ethyl cyanoacetate (B) by reduction, in turn with acetic anhydride, lawson reagent is reacted, and 5-amino-4-carboxylate thiazole compound (D) is obtained;After bromination by NBS, under the catalysis of phosphorus oxychloride, react with tetrahydropyridine indole ketone, generate 2-bromo-6,7-dihydrothiazolo [5'',4'':4',5'] pyrimido [1',2':1,2] pyrindo [3,4-b] indole-4 (12H) -ketone (F), again under alkaline condition, first with Boc piperazine, then by Boc treatment and obtain compound (H);Finally, react with acyl chloride, and 28 different substitution structures of five-ring thiazole indole ketone piperazine amide compound (I1-I28) are synthesized.The 28 compounds are tested on three kinds of cancer cells, and the results show that: 28 compounds have significant inhibitory activity on Hela cervical cancer cells, HT-29 human colon cancer cells and HGC-27 human gastric cancer cells.

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

The invention discloses a novel pyrimidine KRAS-G12C inhibitor as well as a preparation method and application of the novel pyrimidine KRAS-G12C inhibitor. The pyrimidine compound disclosed by the invention has a remarkable inhibition effect on non-small cell lung cancer cells (NCI-H23 and NCI-H358) with high expression of KRAS-G12C, is particularly used as a medicine for treating and / or preventing the non-small cell lung cancer, is simple and efficient in preparation route, and has a good antitumor medicine development and application prospect.

The present disclosure relates generally to crystalline forms of (1S,2S)-N-(2-(4,6- bis(methoxy-d 3)pyrimidin-5-yl)-1-methyl-1H-pyrrolo[2, 3-c]pyridin-5-yl)-2- fluorocyclopropane-1-carboxamide (Compound 1), compositions thereof, and methods of using any of the foregoing.

The application discloses a preparation method of enciferstat bulk drug and belongs to the field of drug synthesis. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (SM) is used as a raw material, and the raw material is reacted with cyclohexylamine under alkaline conditions, and the reaction is washed with water, dried, and concentrated to obtain an intermediate I; the intermediate I is reacted with urea under pressurized heating conditions to prepare an enciferstat drug molecule, the two-step yield is more than 67%, and the purity is more than 99%, the method has a simple operation process, the product is easy to purify, the yield is high, the product purity is high, and a new method for preparing enciferstat bulk drug is provided.

The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.

The present invention relates generally to improved formulations of 6- thioguanine (6-TG), their methods of preparation, and their use in treatment methods. The invention provides a pharmaceutical composition comprising 6-TG, and a polyethylene oxide polymer having a molecular weight of between about 900,000 g / mol and about 9,000,000 g / mol, their methods of preparation, and their use in methods for treating a disease or condition of the distal intestine that responds to 6-TG, wherein the 6-TG is released in the distal intestine.

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).

The invention discloses an anti-oxidation, whitening and brightening composition as well as a preparation method and application thereof. The anti-oxidation, whitening and brightening composition is prepared from the following components in parts by weight: 2 to 6 parts of nicotinamide, 0.5 to 5 parts of tranexamic acid, 1 to 5 parts of nonapeptide-1 solution, 0.5 to 1 part of tetrahydromethylpyrimidine carboxylic acid, 0.5 to 2 parts of pink red plum compound essence, 0.01 to 0.5 part of hydroxyethyl piperazine ethanesulfonic acid, 0.01 to 0.5 part of glabridin and 0.0001 to 0.2 part of glutathione. According to the invention, the composition prepared from nicotinamide, tranexamic acid, nonapeptide-1, tetrahydromethylpyrimidine carboxylic acid, pink-red plum composite essence, hydroxyethyl piperazine ethanesulfonic acid, glabridin and glutathione is prepared into the essence, and the clearance rate of the essence to ABTS free radicals reaches 58% or above, which shows that the essence has very good antioxidant ability; the cell tyrosinase activity inhibition rate of the composition under the concentration of 1.2% (v / v) reaches 51% or above, which shows that the composition has very good whitening and brightening effects.

This invention discloses compounds of Formula I, or pharmaceutically acceptable salts, isomers, racemates, precursors, or solvates thereof. Compounds of Formula I exhibit excellent inhibitory activity against RSK protein kinase, thus showing promise for development into drugs targeting RSK.

The invention relates to the technical field of compound synthesis, in particular to an aminopyrimidine compound, a pharmaceutical composition, application of the aminopyrimidine compound and an intermediate compound. The structural formula of the aminopyrimidine compound is shown as a formula (I), and the aminopyrimidine compound can effectively inhibit the activity of NUAKs kinase, and especially has a good inhibition effect on the activity of NUAK1 kinase and the activity of NNUAK2 kinase. Formula (I).

Provided in the present invention is use of a 2,4-disubstituted-5-fluoropyrimidine derivative or a pharmaceutically acceptable salt thereof in the preparation of drugs for lowering uric acid. The 2,4-disubstituted-5-fluoropyrimidine derivative has the following structural formula (I) and provides a new option for drugs for lowering uric acid.